RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

RECURSION PHARMACEUTICALS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$3.61+0.15 (+4.18%)

Close on Oct 19, 2026

Market cap: $1.92B
P/E (TTM): –
Dividend yield: –

RECURSION PHARMACEUTICALS, INC. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Cash & Equivalents	743	603	401	559	295	267	75	16
Short-Term Investments	–	–	–	0	231	0	–	–
Cash & Short-Term Investments	743	603	401	559	527	267	75	16
Receivables	–	–	–	0	0.03	0.16	–	–
Prepaid Expenses & Other	12	30	–	–	–	–	–	–
Other Current Assets	29	38	40	16	7.51	2.16	–	–
Total Current Assets	813	714	438	570	535	266	–	–
Property, Plant & Equipment	104	141	87	88	65	26	–	–
Gross Property, Plant & Equipment	193	204	131	118	83	36	–	–
Accumulated Depreciation	-89	-63	-45	-30	-19	-9.96	–	–
Operating Lease Right-of-Use Assets	45	66	34	33	33	–	–	–
Goodwill	162	149	52	0.80	0.80	0.80	–	–
Intangible Assets	310	336	36	1.31	1.39	1.69	–	–
Deferred Tax Assets	0.96	1.93	0	–	–	–	–	–
Other Long-Term Assets	13	8.83	0.26	0	0.04	0.65	–	–
Total Assets	1,474	1,449	654	701	610	299	–	–
Accounts Payable	18	22	3.95	4.59	2.82	1.07	–	–
Accrued Expenses	70	82	47	33	32	10	–	–
Current Portion of Long-Term Debt	9.09	8.43	0.04	–	–	–	–	–
Current Debt	9.09	8.43	0.04	–	–	–	–	–
Current Portion of Leases	13	14	6.12	5.95	0	–	–	–
Deferred Revenue (Current)	38	62	36	57	10	10	–	–
Total Current Liabilities	148	187	93	100	47	23	–	–
Long-Term Debt	9.56	19	1.10	0.54	0.63	11	–	–
Long-Term Leases	47	67	43	44	0	–	–	–
Operating Lease Liabilities	59	81	50	50	48	–	–	–
Deferred Tax Liabilities	23	17	1.34	0	–	–	–	–
Other Long-Term Liabilities	2.08	4.73	0	–	–	–	–	–
Total Liabilities	343	414	190	215	67	57	–	–
Total Debt	19	27	1.14	0.54	0.63	11	–	–
Common Stock	0.01	0.00	0.00	0.00	0.00	0	–	–
Additional Paid-In Capital	3,170	2,474	1,431	1,125	943	7.31	–	–
Retained Earnings	-2,076	-1,431	-968	-640	-400	-214	–	–
Comprehensive Income & Other	37	-7.64	0	0	-0.13	0	–	–
Shareholders' Equity	1,131	1,035	463	486	543	-206	-124	-64
Total Equity	1,131	1,035	463	486	543	-206	-124	-64
Total Liabilities & Equity	1,474	1,449	654	701	610	299	–	–
Shares Outstanding(shares)	528	397	234	191	170	22	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 3.5%
Operating margin: -991.7%
Net margin: -945.9%
Return on equity, FY2025: -59.5%

Financial strength

Current ratio: 5.03
Debt to equity: 0.02
Debt to assets: 1.2%
Cash to current liabilities: 455.2%

Valuation

P/E ratio: –
Price to sales: 35.04
Price to book: 2.10
Dividend yield: –